I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.
Details are as follows:
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference | ||
| Conference Date: | February 11-12, 2025 | |
| Format: | Company Presentation and one-on-one meetings | |
| Presentation Time: | Tuesday, February 11, 2025, 4:00 to 4:30 PM ET | |
| Webcast Link: | https://wsw.com/webcast/oppenheimer39/imab/2739496 | |
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.
Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1 617-430-7579
pkelleher@lifesciadvisors.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
